The FDA approved the use of the Animas Vibe Insulin Pump and Continuous Glucose Monitoring System for the management of diabetes in children and adolescents, ages 2 to 17.

Indications: The pump is indicated for continuous subcutaneous insulin infusion for the management of insulin-requiring diabetes.

Dosage and administration: An insulin cartridge with about a 3-day supply of insulin is inserted into the pump. The pump connects to the body with a disposable infusion set that is replaced every few days when the pump is refilled with insulin.

Efficacy and safety: The value of insulin pump therapy has been demonstrated in clinical studies showing that patients who used insulin pump therapy in combination with continuous glucose monitoring obtained lower HbA1c levels compared to those who used multiple daily injections and self-monitoring of blood glucose.

Side effects/risks: Risks include the possible dangers of over delivery and under delivery of insulin, including hypoglycemia and hyperglycemia.

Citation:FDA Approves Animas Vibe Insulin Pump and Continuous Glucose Monitoring System for Use in Children. PR Newswire web site. http://www.prnewswire.com/news-releases/fda-approves-animas-vibe-insulin-pump-and-continuous-glucose-monitoring-system-for-use-in-children-300200262.html. Accessed January 13, 2015.
Important Safety Information. Animas web site. http://www.animas.com/importantsafetyinformation. Accessed January 13, 2015.